MedTrace Logo

Safety Study of AADC Gene Therapy (VY-AADC01) for Parkinson's Disease

NCT01973543 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2020-03-03

No results posted yet for this study

Summary

Safety study of AADC gene transfer (VY-AADC01) in subjects with Parkinson's disease.

Conditions

Interventions

BIOLOGICAL

VY-AADC01

Neurosurgical delivery of VY-AADC01 to the brain.

Sponsors & Collaborators

  • University of California, San Francisco

    collaborator OTHER

  • Veristat, Inc.

    collaborator OTHER

  • Feinstein Institute for Medical Research

    collaborator OTHER

  • Oregon Health and Science University

    collaborator OTHER

  • Voyager Therapeutics

    collaborator INDUSTRY

  • Neurocrine Biosciences

    lead INDUSTRY

Principal Investigators

  • Steve Hersch, MD · Voyager Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2020-01-24
Completion
2020-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01973543 on ClinicalTrials.gov